MIAMI--(BUSINESS WIRE)--Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, announced today that the company would be adding two internationally prominent oncology drug experts to its Board of Directors. Both individuals are intimately familiar with Gibson’s novel and new class of Non-Camptothecin Topoisomerase I drugs and their clinical potential based upon extensive phase I clinical trials.
The two new board members joining Gibson oncology include:
- Mark Cushman, PhD is the Distinguished Professor of Medicinal Chemistry at Purdue University and the Inventor of the Indenoisoquinolines; and
- Nils Brünner, MD, DMSc is Unit Head of Translational Cancer Research at the Danish Cancer Society. He is an experienced investigator on the Indenoisoquinolines both in Denmark and at the NCI.
Mr. Randall Riggs, President & CEO of Gibson Oncology, stated that “Gibson Oncology is pleased to add these two extremely knowledgeable scientists because they will facilitate the development of our phase II trials and allow them to be conducted both in the United States and in Europe.”
About Gibson
Gibson is a private oncology drug development company dedicated to bringing its novel, cost-effective, and very well-tolerated Indeno anti-cancer treatments to market. Gibson intends to develop these novel anti-cancer drugs in advanced-stage cancer patients as single agent and in combination treatments with both immunotherapy and targeted therapies.
